

Resource Summary Report

Generated by [kravitz2](#) on Sep 17, 2026

BD Biosciences: LSRFortessa Cell Analyzer

RRID:SCR_018655

Type: Tool

Proper Citation

BD Biosciences: LSRFortessa Cell Analyzer (RRID:SCR_018655)

Resource Information

URL: <https://www.bdbiosciences.com/en-us/instruments/research-instruments/research-cell-analyzers/lrfortessa>

Proper Citation: BD Biosciences: LSRFortessa Cell Analyzer (RRID:SCR_018655)

Description: BD LSRFortessa system can be configured with up to 7 lasers, blue, red, violet, UV and yellow-green. The instrument can accommodate the detection of up to 18 colors simultaneously with defined set of optical filters that meet or exceed the majority of today's assay requirements. BD FACSDiva software controls the efficient setup, acquisition, and analysis of flow cytometry data from the BD LSRFortessa workstation. The software is common across BD FACS instrument families, including the BD FACSCanto cell analyzer and BD FACSAria cell sorter systems.

Synonyms: BD LSRFortessa

Resource Type: instrument resource

Keywords: Flow cytometer, BD flow cytometer, multicolor flow cytometry assay, cell analysis, cell analyzer, laser, detect colors simultaneously, instrument, equipment

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_018655.pdf

Resource Name: BD Biosciences: LSRFortessa Cell Analyzer

Resource ID: SCR_018655

Alternate IDs: SCR_01960, SCR_019601, SCR_019602, SCR_019600, Model_Number_LSRFortessa, SCR_019605

Record Creation Time: 20220129T080341+0000

Record Last Update: 20260912T195904+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: LSRFortessa Cell Analyzer.

No alerts have been found for BD Biosciences: LSRFortessa Cell Analyzer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 75 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Suresh V, et al. (2026) Modelling EWS::FLI1 protein fluctuations reveal determinants of tumor plasticity in Ewing sarcoma. EMBO molecular medicine, 18(2), 646.

Nelson MC, et al. (2026) MicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5. Cancer research communications, 6(2), 359.

Zhou Z, et al. (2026) Using an Unbiased Coexpression Network to Reveal Cross-Talking Pathways of Phosphoinositide-3-Kinase Regulatory Subunit 1 in Skin Aging and Rejuvenation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(2), e71466.

Ullrich L, et al. (2026) Protocol for multiplexed detection of antibody binding to cell-surface-expressed hemagglutinin by flow cytometry. STAR protocols, 7(2), 104614.

Choudhury PR, et al. (2026) Atorvastatin pre-exposure in hypercholesterolemia remedies 27HC mediated dendritic cell dysfunctions in triple-negative breast cancer. Molecular therapy. Oncology, 34(3), 201250.

Heiduk M, et al. (2026) Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer. JCI insight, 11(2).

Anderko RR, et al. (2026) Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(3), 596.

Maerz MD, et al. (2026) BCG vaccination induces antibacterial effector functions among V α 1/3 T cells that are associated with protection against tuberculosis. Cell reports. Medicine, 102536.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. Cell reports. Medicine, 7(7), 102922.

Lohbihler M, et al. (2026) Human pluripotent stem cell-derived atrioventricular node-like pacemaker cells exhibit biological conduction bridge properties. *Cell stem cell*, 33(4), 571.

Guilz NC, et al. (2026) Autosomal dominant CDC45 deficiency with allelic expression bias causes a novel genetic disease of the immune system. *bioRxiv : the preprint server for biology*.

Wu P, et al. (2026) A circRNA neoantigen vaccine elicits potent antitumor immunity and synergizes with checkpoint blockade in melanoma. *Cancer letters*, 648, 218459.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. *Cell reports. Medicine*, 7(3), 102644.

Fahmy AM, et al. (2026) STING dampens the unfolded protein response to enable the presentation of self-antigens on MHC-I during inflammation. *Cell reports*, 45(6), 117497.

Guercio BJ, et al. (2026) Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1434.

Tang E, et al. (2026) Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. *Cancer immunology research*, 14(8), 1292.

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. *Cancer research communications*, 6(7), 1619.

Ma T, et al. (2025) Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells. *Cancer research*, 85(19), 3596.

Boccardo S, et al. (2025) Dynamics of tissue repair regulatory T cells and damage in acute *Trypanosoma cruzi* infection. *PLoS pathogens*, 21(1), e1012906.

Bischoff ME, et al. (2025) Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma. *Cancer discovery*, 15(2), 401.